Adagrasib Clinical Trials

9 actively recruiting trials across 7 locations

▲ +1 trial since August 2026

Also known as: BMS-986503, BMS-986503; KRAZATI®, KRAS G12C Inhibitor MRTX849, KRAZATI, Krazati +5 more

Pipeline

Phase 1: 3Phase 2: 3Phase 3: 1Phase 1/2: 1Phase 2/3: 1

Top Sponsors

Mirati Therapeutics Inc.3
M.D. Anderson Cancer Center2
Ryan Gentzler, MD1
Kura Oncology, Inc.1
City of Hope Medical Center1

Indications

Cancer9
Lung Cancer7
Non Small Cell Lung Cancer2
Solid Tumors With HRAS Alterations1
Non-Clear Cell Renal Cell Carcinoma (nccRCC)1

Goodyear, Arizona2 trials

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

CTCA at Western Regional Medical Center

Phase 2

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Local Institution - 007-556-A

Phase 2/3

Phoenix, Arizona2 trials

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Local Institution - 0005

Phase 2

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Mayo Clinic Comprehensive Cancer Center

Phase 1

Birmingham, Alabama1 trial

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0347

Phase 3

Boston, Massachusetts1 trial

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Massachusetts General Hospital Cancer Center

Phase 1/2

Hackensack, New Jersey1 trial

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

John Theurer Cancer Center at Hackensack University Medical Center

Phase 1

Columbus, Ohio1 trial

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Ohio State University Comprehensive Cancer Center

Phase 2

Houston, Texas1 trial

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

The University of Texas M. D. Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.